News
Research updates, company news, and insights into autoimmune diagnostics.
RESEARCH
•
MAR 2026
Anifrolumab treatment may particularly benefit IFN-1 High Lupus patients
The biologic anifrolumab was developed by AstraZeneca and received FDA approval on August 2, 2021, for use alongside standard therapy in adults with moderate to severe systemic lupus erythematosus. This approval marked a significant milestone in targeted autoimmune therapy.
Read article →
RESEARCH
•
MAR 2026
Anifrolumab treatment may particularly benefit IFN-1 High Lupus patients
The biologic anifrolumab was developed by AstraZeneca and received FDA approval on August 2, 2021, for use alongside standard therapy in adults with moderate to severe systemic lupus erythematosus. This approval marked a significant milestone in targeted autoimmune therapy.
Read article →
•
May 18, 2022
DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) for Systemic Lupus Erythematosus
IFN-1 gene signature testing represents the advancement of precision medicine beyond cancer in autoimmune disease
Research
•
May 14, 2026
Precision Medicine using Modular Genomics
A simple look at how RNA-based testing can help uncover patterns in immune system activity and support more informed care decisions.
Research
•
February 27, 2020
DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device
Learn how patient-friendly testing can reduce barriers, improve convenience, and help people stay more connected to their health journey.
All articles
May 2023
COMPANY
5 gene Interferon Test and Deucrava
Nov 2022
Company
Cenerimod ACR 2022 abstract
JUL 2025
RESEARCH
Characterizing Arthritis Subtypes in SL.
May 2025
COMPANY
Enpatoran SLE Eular 2025
May 2022
Research
Morand IFN-1 High Longitudinal Analysis 2022
May 2026
Research
Tuoma IFN-1 Status and Clinical Manifestations
Connect with us
Discover how RNA-based diagnostics can provide the insights to better understand autoimmune diseases.
Learn more
Stay in the know.
Get the latest updates and news.
DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being.
News
Research updates, company news, and insights into autoimmune diagnostics.
Company
•
September 8, 2026
Three DxTerity Abstracts Accepted for Presentation at ACR Convergence 2026
Studies examine the Type I interferon gene signature and a low-density granulocyte neutrophil signature as tools for identifying lupus patients with severe disease, inadequate response to standard of care, and signs of resistance to anifrolumab therapy
Read article →
Company
•
September 8, 2026
DxTerity Opens Purpose-Built Torrance Headquarters and Laboratory
DxTerity opens a purpose-built headquarters and clinical laboratory in Torrance, California, to support growing demand for its RNA-based genomic testing.
Read article →
•
May 18, 2022
DxTerity Receives New York Authorization for Type 1 Interferon (IFN-1) for Systemic Lupus Erythematosus
IFN-1 gene signature testing represents the advancement of precision medicine beyond cancer in autoimmune disease
Research
•
May 14, 2026
Precision Medicine using Modular Genomics
A simple look at how RNA-based testing can help uncover patterns in immune system activity and support more informed care decisions.
Research
•
February 27, 2020
DxTerity Receives CE Mark for DxCollect® Fingerstick Blood RNA Stabilization Device
Learn how patient-friendly testing can reduce barriers, improve convenience, and help people stay more connected to their health journey.
All articles
May 2023
COMPANY
5 gene Interferon Test and Deucrava
Nov 2022
Company
Cenerimod ACR 2022 abstract
JUL 2025
RESEARCH
Characterizing Arthritis Subtypes in SL.
May 2025
COMPANY
Enpatoran SLE Eular 2025
May 2022
Research
Morand IFN-1 High Longitudinal Analysis 2022
May 2026
Research
Tuoma IFN-1 Status and Clinical Manifestations
Connect with us
Discover how RNA-based diagnostics can provide the insights to better understand autoimmune diseases.
Learn more
Stay in the know.
Get the latest updates and news.
DxTerity’s patient-focused mission is to bring the power of at-home RNA-based genomic monitoring to improve the management of immune-mediated diseases and overall patient well-being.